The European Medicines Agency (EMA) ?? Europe’s main drug licensing body ?? is in the midst of a massive fraud enquiry regarding the diabetes drug, Mediator. The EMA, which is primarily funded by the very pharmaceutical industry it is supposed to regulate, is being investigated by the European Anti-Fraud Office (OLAF) for alleged conflicts of interest.
Mediator hit the European market nearly 33 years ago and was mainly prescribed to diabetes sufferers in France, Italy and Spain. Alarm bells started ringing in 1998 when Italy and Spain withdrew the drug from the market and since then, studies have estimated that the drug has caused between 500 and 2000 deaths.